Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in Boao Lecheng Pilot Zone
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
The journal "Cost Effectiveness and Resource Allocation" is committed to providing a multidimensional academic platform, focusing on exploring and analyzing the application and impact of cost-effectiveness analysis in various fields. The journal not only pays attention to the innovation of theoretical frameworks and methodologies but also values economic evaluations in practical applications, including cost-benefit research in industries such as healthcare, education, and environmental policy.
The journal also focuses on resource allocation issues from an international perspective, discussing the strategies and challenges of different countries and regions in resource allocation, and how to achieve optimal resource allocation under the background of globalization. By publishing these studies, the journal aims to provide empirical research foundations and decision-making support for policymakers, health economists, and professionals in related fields.
中科院SCI分區(qū)
Cost Effectiveness And Resource Allocation雜志中科院分區(qū)信息